These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30298129)

  • 41. Overcoming Challenges Facing Advanced Therapies in the EU Market.
    Abou-El-Enein M; Elsanhoury A; Reinke P
    Cell Stem Cell; 2016 Sep; 19(3):293-7. PubMed ID: 27588746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The use of nanotechnology in medicinal products in the light of European Union law].
    Jurewicz M
    Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How Regenerative Medicine Stakeholders Adapt to Ever-Changing Technology and Regulatory Challenges? Snapshots from the World TERMIS Industry Symposium (September 10, 2015, Boston).
    Bayon Y; Van Dyke M; Buelher R; Tubo R; Bertram T; Malfroy-Camine B; Rathman M; Ronfard V
    Tissue Eng Part B Rev; 2017 Apr; 23(2):159-162. PubMed ID: 27771996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medicinal products in the European Union--between harmonization and divergence.
    Lojko N
    Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
    Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
    de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
    Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
    Renner M; Anliker B; Sanzenbacher R; Schuele S
    Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances and Challenges in the Development of Gene Therapy Medicinal Products for Rare Diseases.
    Bueren JA; Auricchio A
    Hum Gene Ther; 2023 Sep; 34(17-18):763-775. PubMed ID: 37694572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 59. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenges of running a GMP facility for regenerative medicine in a public hospital.
    Viganò M; Giordano R; Lazzari L
    Regen Med; 2017 Oct; 12(7):803-813. PubMed ID: 29115906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.